Leukemia and Lymphoma

The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.

Latest News

Child standing on scale | Image Credit: Protsenko Dmitriy - stock.adobe.com
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients

January 13th 2025

Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.

Hodgkin lymphoma | Image credit: Dr_Microbe - stock.adobe.com
BrECADD Regimen Reaches “Unprecedently High” PFS for Patients With Hodgkin Lymphoma

June 18th 2024

FDA Approved - chrisdorney - stock.adobe.com.jpg
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma

March 7th 2024

Red Blood Cells - Design Cells stock.adobe.com
alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden

December 22nd 2023

Highlights from ASH 2023
ICYMI: Highlights From ASH 2023

December 20th 2023

Continuing Medical Education
View All
June 17th 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology
June 17th 2025

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer
June 17th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer

More News

Two-Year OS Doubles for Patients With Philadelphia-Positive Relapsed ALL After HSCT
January 12th 2022

Two-Year OS Doubles for Patients With Philadelphia-Positive Relapsed ALL After HSCT

Allison Inserro
While acute lymphoblastic leukemia (ALL) was still the primary cause of death, researchers saw a steady increase in 2-year survival from 27.8% to 54.8% even as patient age at the time of relapse after allogeneic hematopoietic stem cell transplantation (HCST) increased.
NCCN Publishes New Guidebook for Patients at Risk of GVHD
January 10th 2022

NCCN Publishes New Guidebook for Patients at Risk of GVHD

Jared Kaltwasser
Graft-versus-host disease (GVHD) is common, yet it is poorly understood and its symptoms can be difficult to recognize.
Lack of Monitoring Among Older Patients With CML Linked to Poor TKI Adherence
January 8th 2022

Lack of Monitoring Among Older Patients With CML Linked to Poor TKI Adherence

AJMC Staff
The findings showing that older patients with chronic myeloid leukemia (CML) had poor adherence to tyrosine kinase inhibitors (TKIs) was presented last month during the American Society of Hematology Meeting & Exposition.
Steven Pergam, MD, MPH
January 7th 2022

Dr Steven Pergam Discusses NCCN's Preference for mRNA Vaccines

Mary Caffrey Hayden E. Klein
Steven Pergam, MD, MPH, director of infection prevention at Seattle Cancer Care Alliance and infectious disease physician at Fred Hutchinson Cancer Research Center, discusses the National Comprehensive Cancer Network's (NCCN) preference for mRNA vaccines and how they work differently.
Top leukemia and lymphoma articles of 2021
December 28th 2021

Top 5 Most-Read Articles in Leukemia and Lymphoma for 2021

Laura Joszt, MA
Articles on treating and protecting patients with blood cancers from COVID-19 and the positive results of zanubrutinib to treat leukemia and lymphoma were among the most read of the year.
ASH Posters Evaluate COVID-19 Risk Among Patients With Blood Cancers
December 24th 2021

ASH Posters Evaluate COVID-19 Risk Among Patients With Blood Cancers

Laura Joszt, MA
Research using data from the ASH Research Collaborative COVID-19 Registry for Hematology identified risk factors for severe infection and mortality for patients with blood cancers who were infected with COVID-19.
Study Shows Need for Earlier Conversations About End-of-Life Care With Patients Who Have High-Risk AML
December 18th 2021

Study Shows Need for Earlier Conversations About End-of-Life Care With Patients Who Have High-Risk AML

Mary Caffrey
Third mRNA COVID-19 Vaccine Helps Some Patients With Blood Cancer Produce Antibodies for First Time
December 18th 2021

Third mRNA COVID-19 Vaccine Helps Some Patients With Blood Cancer Produce Antibodies for First Time

AJMC Staff
There are 2 such vaccines now in use in the United States; the Pfizer-BioNTech vaccine is fully approved for the first 2 doses for those 16 and older, and the Moderna vaccine has an emergency use authorization for those 18 and older.
Exercise
December 9th 2021

HIIT May Maintain Health in Older Patients With Treatment-Naïve CLL

Laura Joszt, MA
High-intensity interval training (HIIT) may maintain health, including immune cell function, for patients with treatment-naïve chronic lymphocytic leukemia (CLL).
Doctor with patient in bed
December 4th 2021

Can Earlier Use of Palliative Care Improve End-of-Life Outcomes in AML?

Laura Joszt, MA
Setting up a palliative care consultation program for patients with acute myeloid leukemia (AML) improved some aspects of care.
Targeted Therapies Offer Attractive Treatment Approach for Elderly/Unfit Patients With CLL
December 3rd 2021

Targeted Therapies Offer Attractive Treatment Approach for Elderly/Unfit Patients With CLL

Jaime Rosenberg
The researchers outlined potential treatment options for this patient population since the emergence and uptake of targeted treatments.
Happy child in hospital bed
November 24th 2021

Drug Combination Used in Adults Can Benefit Children With Acute Promyelocytic Leukemia

Laura Joszt, MA
All-trans retinoic acid and arsenic trioxide used together can let children avoid treatment with convention chemotherapy, which has more adverse effects.
hospital
November 20th 2021

Hospitals Lack Medication Needed for Form of AML, Study Finds

Allison Inserro
Although acute promyelocytic leukemia is highly treatable in early stages, the medication needed stop hematologic emergencies, all-trans retinoic acid, is often not available, a new study says.
Doctor and patient
November 16th 2021

HRQOL Decreased During and Immediately After CAR T-Cell Therapy for DLBCL

Laura Joszt, MA
Prior to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), patients experienced a decrease in health-related quality of life (HRQOL), which was further impaired during and immediately after CAR T therapy.
Safety Analysis Finds Zanubrutinib’s Toxicity Profile Is Consistent With Other BTK Inhibitors
November 13th 2021

Safety Analysis Finds Zanubrutinib’s Toxicity Profile Is Consistent With Other BTK Inhibitors

Laura Joszt, MA
A safety analysis of 6 trials found zanubrutinib has a toxicity profile consistent wth other Bruton tyrosine kinase (BTK) inhibitors.
Researchers Report Further Analysis of Zanubrutinib Monotherapy for R/R MCL
November 13th 2021

Researchers Report Further Analysis of Zanubrutinib Monotherapy for R/R MCL

Allison Inserro
Fewer Blood Transfusions for Patients With AML Has Humanistic, Economic Benefits
November 5th 2021

Fewer Blood Transfusions for Patients With AML Has Humanistic, Economic Benefits

Laura Joszt, MA
Posters presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting analyzed patient and physician perspectives on blood transfusions in acute myeloid leukemia (AML).
syringe and pills
November 3rd 2021

Tazemetostat Yields Fewer Safety Outcomes, Lower AE-Associated Costs vs PI3 Kinase Inhibitors

Gianna Melillo
Two analyses presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting highlighted the safety and cost benefits of tazemetostat compared with phosphoinositide 3 (PI3) kinase inhibitors for patients with follicular lymphoma.
health care costs
October 30th 2021

The Cost of Treating AEs Due to CAR T-Cell Therapy Treatment

Laura Joszt, MA
Two posters presented at AMCP Nexus 2021 analyzed the costs of treating cytokine release syndrome and neurological events, 2 common adverse events (AEs) of chimeric antigen receptor (CAR) T-cell therapy.
health care cost
October 25th 2021

Comparing Costs and HRU for Tisagenlecleucel vs Axicabtagene Ciloleucel for DLBCL

Laura Joszt, MA
Posters presented at AMCP Nexus 2021 evaluated the health care resource utilization (HRU) and costs associated with the chimeric antigen receptor T-cell therapies tisagenlecleucel and axicabtagene ciloleucel.
Zanubrutinib Cost-effective and Cost Saving vs Ibrutinib in Waldenström Macroglobulinemia
October 22nd 2021

Zanubrutinib Cost-effective and Cost Saving vs Ibrutinib in Waldenström Macroglobulinemia

Laura Joszt, MA
Posters presented at the AMCP Nexus 2021 meeting reviewed the cost-effectiveness and cost per response for zanubrutinib vs ibrutinib.
Muscle Loss in Immunochemotherapy for DLBCL
October 17th 2021

Investigators Document Muscle Loss During Immunochemotherapy for DLBCL

Deanna Ferreri, PhD
Investigators in a retrospective study of patients with diffuse large B-cell lymphoma (DLBCL) sought to understand the correlation between muscle loss and immunochemotherapy.
Lori Pierce, MD, FASTRO, FASCO
October 12th 2021

Addressing Disparities in Cancer Care and Beyond: What Can Be Done Now?

Alexander J. Alvarnas
Conversations on CAR T: Study of Checkpoint Inhibitors After Transplant Bolsters Case for CAR T, Skarbnik Says
October 11th 2021

Conversations on CAR T: Study of Checkpoint Inhibitors After Transplant Bolsters Case for CAR T, Skarbnik Says

Mary Caffrey
Conversations on CAR T: UAB’s Mehta Discusses Opportunities and Challenges
October 11th 2021

Conversations on CAR T: UAB’s Mehta Discusses Opportunities and Challenges

Mary Caffrey
Elevated Risks of NHL, Lung Cancer Increase Mortality in Recipients of Organ Transplant
October 9th 2021

Elevated Risks of NHL, Lung Cancer Increase Mortality in Recipients of Organ Transplant

Laura Joszt, MA
People who receive organ transplants have an elevated risk of developing cancer, particularly lung cancer and non-Hodgkin lymphoma (NHL).
Karen Winkfield, MD, PhD
October 7th 2021

Dr Karen Winkfield on Taking Action to Address Disparities in Cancer

There is a lot of evidence on the disparities in cancer care, but less on how to take those findings and turn them into actionable items to address the problem, said Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance.
dna graphic
October 7th 2021

Review Outlines Progress on GE-Based Biomarkers for CML

Gianna Melillo
A recently published review outlines progress made in discovering biomarkers for chronic myeloid leukemia (CML).
Patient Characteristics Impact Effectiveness of TKIs in CML and AEs Experienced
October 1st 2021

Patient Characteristics Impact Effectiveness of TKIs in CML and AEs Experienced

Laura Joszt, MA
Dosing from pivotal phase 3 trials of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) is not optimal for real-world patients who experience different efficacy and adverse events (AEs).
Picture of a leukemia cell
September 29th 2021

Second-Generation BTK Inhibitors Seek to Build Off Ibrutinib Success in CLL

Jaime Rosenberg
These second-generation inhibitors include acalabrutinib, zanubrutinib, and tirabrutinib, and researchers hope they can overcome the off-target toxicity and treatment resistance that can be experienced with ibrutinib.
<12345678910
...
19>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo